Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany; and.
Clinical Pharmacology, Institute AGATE gGmbH, Pentling, Germany.
Ther Drug Monit. 2022 Apr 1;44(2):345-350. doi: 10.1097/FTD.0000000000000908.
Therapeutic drug monitoring (TDM) of antiseizure medications (ASMs) is widely used to guide therapy, avoid toxicity, and assess patient compliance. Commercial immunologic quantification methods are common practice; however, as they are only applicable to one specific drug and prone to cross-reacting metabolites, their practical applicability is limited. In this article, the authors proposed a high-performance liquid chromatography method using ultraviolet detection (HPLC-UV) for simultaneous quantification of 11 ASMs and active metabolites (carbamazepine, felbamate, lacosamide, lamotrigine, levetiracetam, phenobarbital, phenytoin, primidone, zonisamide, carbamazepine-10,11-epoxide, and licarbazepine) in serum.
Chromatographic separation was performed on a Phenomenex Luna PFP(2) (3-µm particle size; 150 × 4.6 mm i.d.) analytical column. The mobile phase comprised phosphate buffer (20 mM; pH 3), acetonitrile (ACN), and methanol using gradient elution. Analyses were conducted at 35°C and a 1.3-mL/min flow rate. The detection wavelength for all analytes was 210 nm. The samples were prepared by protein precipitation using ACN.
The HPLC-UV method was validated according to the FDA guidelines and applied to measure patient samples in TDM. Calibration curves showed excellent linearity (r2 > 0.99) and covered the entire reference range for each analyte. Intraday and interday imprecisions and inaccuracies were <10% for all samples. Extensive stability testing showed no significant degradation (<15%), and interference measurements additionally ensured clinical applicability. Furthermore, the sensitivity was comparable with that of previously published HPLC methods using mass spectrometry.
The authors developed an HPLC-UV method for the simultaneous quantification of 11 ASMs in the human serum and demonstrated its practical applicability in TDM. The method requires only standard laboratory equipment and simple sample preparation, making TDM available in less specialized laboratories.
抗癫痫药物(ASM)的治疗药物监测(TDM)广泛用于指导治疗、避免毒性和评估患者依从性。商业免疫定量方法是常见的做法;然而,由于它们仅适用于一种特定的药物,并且容易与交叉反应的代谢物发生交叉反应,因此它们的实际适用性有限。在本文中,作者提出了一种使用紫外检测的高效液相色谱法(HPLC-UV),用于同时定量血清中的 11 种 ASM 和活性代谢物(卡马西平、苯妥英、左乙拉西坦、苯巴比妥、苯妥英、普瑞巴林、丙戊酸、苯妥英、拉莫三嗪、卡马西平-10、11-环氧化物和利卡西平)。
色谱分离在 Phenomenex Luna PFP(2)(3-µm 粒径;150×4.6mm i.d.)分析柱上进行。流动相由磷酸盐缓冲液(20mM;pH3)、乙腈(ACN)和甲醇组成,采用梯度洗脱。分析在 35°C 和 1.3mL/min 的流速下进行。所有分析物的检测波长为 210nm。样品通过 ACN 沉淀蛋白进行制备。
根据 FDA 指南验证了 HPLC-UV 方法,并将其应用于 TDM 中测量患者样本。校准曲线显示出极好的线性(r2>0.99),涵盖了每个分析物的整个参考范围。所有样品的日内和日间精密度和准确度均<10%。广泛的稳定性测试显示无明显降解(<15%),并且干扰测量进一步确保了临床适用性。此外,灵敏度与使用质谱法的先前发表的 HPLC 方法相当。
作者开发了一种用于同时定量人血清中 11 种 ASM 的 HPLC-UV 方法,并证明了其在 TDM 中的实际适用性。该方法仅需要标准实验室设备和简单的样品制备,使 TDM 可在较少专业的实验室中使用。